Berry, M.D.; Gainetdinov, R.R.; Hoener, M.C.; Shahid, M. Pharmacology of human trace amine-associated receptors: Therapeutic oppor-tunities and challenges. Pharmacol. Ther., 2017, 180, 161-180.
[http://dx.doi.org/10.1016/j.pharmthera.2017.07.002] [PMID: 28723415]

Gainetdinov, R.R.; Hoener, M.C.; Berry, M.D. Trace amines and their receptors. Pharmacol. Rev., 2018, 70(3), 549-620.
[http://dx.doi.org/10.1124/pr.117.015305] [PMID: 29941461]

Schwartz, M.D.; Canales, J.J.; Zucchi, R.; Espinoza, S.; Sukhanov, I.; Gainetdinov, R.R. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin. Ther. Targets, 2018, 22(6), 513-526.
[http://dx.doi.org/10.1080/14728222.2018.1480723] [PMID: 29798691]

Rutigliano, G.; Accorroni, A.; Zucchi, R. The case for TAAR1 as a modulator of central nervous system function. Front. Pharmacol., 2018, 8, 987.
[http://dx.doi.org/10.3389/fphar.2017.00987] [PMID: 29375386]

Tonelli, M.; Cichero, E. Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present). Expert Opin. Ther. Pat., 2020, 30(2), 137-145.
[http://dx.doi.org/10.1080/13543776.2020.1708900] [PMID: 31865810]

Cichero, E.; Tonelli, M. Targeting species-specific trace amine-associated receptor 1 ligands: to date perspective of the rational drug design process. Future Med. Chem., 2017, 9(13), 1507-1527.
[http://dx.doi.org/10.4155/fmc-2017-0044] [PMID: 28791911]

Guariento, S.; Tonelli, M.; Espinoza, S.; Gerasimov, A.S.; Gainetdinov, R.R.; Cichero, E. Rational design, chemical synthesis and biologi-cal evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists. Eur. J. Med. Chem., 2018, 146, 171-184.
[http://dx.doi.org/10.1016/j.ejmech.2018.01.059] [PMID: 29407948]

Francesconi, V.; Cichero, E.; Kanov, E.V.; Laurini, E.; Pricl, S.; Gainetdinov, R.R.; Tonelli, M. Novel 1-amidino-4-phenylpiperazines as potent agonists at human TAAR1 receptor: Rational design, synthesis, biological evaluation and molecular docking studies. Pharmaceuticals (Basel), 2020, 13(11), E391.
[http://dx.doi.org/10.3390/ph13110391] [PMID: 33202687]

Cichero, E.; Espinoza, S.; Tonelli, M.; Franchini, S.; Gerasimov, A.S.; Sorbi, C.; Gainetdinov, R.R.; Brasili, L.; Fossa, P. A homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists. MedChemComm, 2016, 7(2), 353-364.
[http://dx.doi.org/10.1039/C5MD00490J]

Dodd, S.; Carvalho, F. A.; Puri, B.K.; Maes, M.; Bortolasci, C.C.; Morris, G.; Berk, M. Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry? Neurosci. Biobehav. Rev., 2021, 120, 537-541.
[http://dx.doi.org/10.1016/j.neubiorev.2020.09.028] [PMID: 33031817]

Hoener, M.; Raab, S.; Risterucci, C.; Sewing, S. Combinations comprising atypical antipsychotics and Taar1 agonists. WO2012016879A1, 2012.

Galley, G.; Hoener, M.; Norcross, R.; Pflieger, P. 5-Ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of Taar. WO2017157873A1, 2017.

Koblan, K.S.; Kent, J.; Hopkins, S.C.; Krystal, J.H.; Cheng, H.; Goldman, R.; Loebel, A. A non-D2-receptor-binding drug for the treatment of schizophrenia. N. Engl. J. Med., 2020, 382(16), 1497-1506.
[http://dx.doi.org/10.1056/NEJMoa1911772] [PMID: 32294346]

Correll, C.U.; Koblan, K.S.; Hopkins, S.C.; Li, Y. Heather Dworak; Goldman, R.; Loebel, A. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr., 2021, 7(1), 63.
[http://dx.doi.org/10.1038/s41537-021-00190-z] [PMID: 34887427]

Galluppi, G.R.; Polhamus, D.G.; Fisher, J.M.; Hopkins, S.C.; Koblan, K.S. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia. CPT Pharmacometrics Syst. Pharmacol., 2021, 10(10), 1245-1254.
[http://dx.doi.org/10.1002/psp4.12692] [PMID: 34292664]

Kantrowitz, J.T. Trace amine-associated receptor 1 as a target for the development of new antipsychotics: current status of research and future directions. CNS Drugs, 2021, 35(11), 1153-1161.
[http://dx.doi.org/10.1007/s40263-021-00864-3] [PMID: 34655036]